Feed RAPP
RA

Rapport Therapeutics, Inc. Common Stock

RAPP · NASDAQ

$40.45 -5.93% (-$2.55)
1M -18.00%
Market Cap $2.01B
P/E Ratio -
Div. Yield -
ROE 29.02%
Piotroski F-Score Weak
2/9
Valuation
21 /100
Expensive
P/B 4.74x
P/S 100.32x
EV/FFO N/A
Growth
100 /100
Growing
Book val. growth 191.81%
FCF growth N/A
EPS growth N/A
Profitability
20 /100
Weak
Op. margin 767.58%
Gross margin 100.00%
FCF margin 485.75%
Quality
1 /100
Poor
ROA 29.88%
ROIC 35.45%
Asset turnover 0.04x
Debt
100 /100
Low
Current ratio 15.72x
Debt/Equity 0.02x
Debt/Assets N/A
Stability
31 /100
Unstable
Profitable years 0
Beta 1.03x
EPS volatility 169.43%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about RAPP
Online

Sector

Healthcare

Industry

Biotechnology

CEO

Abraham N. Ceesay

Employees

84

Headquarters

Boston

Upcoming events

05 NOV

Earnings

Upcoming earnings report

45d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.